This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brian, S. R. Articles by Inzucchi, S. E. Search for Related Content PubMed PubMed Citation Articles by Brian, S. R. Articles by Inzucchi, S. E. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information High Risk Pregnancy Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology Female Endocrinology

Treatment of Acromegaly with Pegvisomant during Pregnancy: Maternal and Fetal Effects

Section of Endocrinology (S.R.B., S.E.I.), Yale University School of Medicine, New Haven, Connecticut 06510; Medizinische Klinik-Innenstadt (M.B.), Ludwig-Maximilians Universität, D-80336 Munich, Germany; Endocrine Care (M.P.W.), Pfizer Global Pharmaceuticals, New York, New York 10017; and Department of Pediatrics (S.A.W.), Yale University School of Medicine, New Haven, Connecticut 06520-8064

Address all correspondence and requests for reprints to: Susan Riddle Brian, M.D., Department of Endocrinology, Yale-New Haven Hospital, 85 Hyde Street, New Haven, Connecticut 06512. E-mail: Susan.Brian{at}yale.edu.

Objective: Our objective was to describe the first case of the successful use of pegvisomant during pregnancy in a woman with acromegaly.

Design: We present the case of a 26-yr-old female with acromegaly who had failed surgical and subsequent medical therapy but whose disease was well controlled on pegvisomant. She then conceived and was continued on pegvisomant throughout pregnancy. We then collected both maternal and cord blood samples at parturition, and later analyzed her breast milk.

Results: Maternal IGF-I was well controlled during gestation. Fetal GH and IGF-I were within the normal range. Maternal pegvisomant levels were consistent with a 25-mg daily dosage. Fetal pegvisomant levels were minimal and near the range detected in untreated acromegalic patients, likely representing minimal cross-reactivity from endogenous GH or spurious contamination by maternal blood. GH variant levels in the maternal blood and the cord blood were both within the normal ranges. Pegvisomant levels in breast milk were below the lower limit of quantification of the assay and similar to those observed when analyzing breast milk samples from normal mothers in the same assay. Fetal growth parameters were normal; the baby was healthy and showed no adverse signs.

Conclusions: Pegvisomant therapy during gestation was safe and effective in our patient. Transplacental passage of pegvisomant is either absent or minimal, with a concentration highly unlikely to convey any significant pharmacodynamic effects on the fetal GH and IGF-I system. In addition, there is no evidence of substantial secretion of pegvisomant into breast milk.

This article has been cited by other articles:

				C. E. Higham and P. J. Trainer Growth hormone excess and the development of growth hormone receptor antagonists Exp Physiol, November 1, 2008; 93(11): 1157 - 1169. [Abstract] [Full Text] [PDF]